Michael Hartleib, MD, MSc, FRCPC
Chief of Staff
Peterborough Regional Health Centre
Queen's University
Tara Seirafi (she/her/hers)
Medical Student
McGill University
Daniel Gaudet, MD, PhD (he/him/his)
Prof.
ECOGENE-21 QC and Université de Montréal
Chunmei Qi, n/a
Cardiovascular resident
The Second Affiliated Hospital of Xuzhou Medical University
Stephanie LeBlanc, PhD, MD (she/her/hers)
Cardiology Resident
Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval
Abstract presentations in this session showcase how artificial intelligence and quality improvement are shaping coronary artery disease care. Topics include a machine learning model predicting mortality in T2DM-CHD patients, a systematic review of FFR-guided revascularization, and real-world data on LDL-lowering gene editing therapies—highlighting the role of data-driven innovation in clinical practice.
Presentations:
Tara Seirafi – Fractional Flow Reserve-Guided Complete Versus Culprit-Only Revascularization in Patients with Myocardial Infarction and Multivessel Disease: A Systematic Review and Meta-Analysis
Daniel Gaudet – Initial Results from the Phase 1B HEART-2 Study of Verve-102, an Investigational Base Editing Medicine Designed to Inactivate PCSK9 in the Liver and Durably Lower LDL Cholesterol
Chunmei Qi – Prognostic Value of the TyG Index and Its Derivatives for All-Cause Mortality in T2DM-CHD Patients: A SHAP-Interpretable Machine Learning Model Using NHANES Data
Stéphanie LeBlanc – Ventricular Septal Defect After Myocardial Infarction: Time for a New Paradigm?